Clarity Pharmaceuticals announces US FDA grants Cu-64 SARTATE™ Orphan Drug Designation for the clinical management of neuroblastoma
Sydney, Australia 19 May 2020 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for 64Cu-SARTATE™ as a diagnostic agent for the clinical management of neuroblastoma. “This milestone comes shortly after the FDA…